Literature DB >> 30803975

Pharmacokinetics of Levofloxacin in Children Treated for Exposure to Drug-Resistant Tuberculosis.

Hamidah Hussain1, Courtney M Yuen2,3, Amyn A Malik4,1,5, Meredith B Brooks6, Sara Siddiqui4, Junaid Fuad4, Charles A Peloquin7, Farhana Amanullah4, Maria Jaswal4, Mercedes C Becerra6,3.   

Abstract

Levofloxacin is used to treat and prevent drug-resistant tuberculosis in children. We assessed levofloxacin serum drug concentrations in 24 children aged 2 to 10 years who received levofloxacin-based tuberculosis preventive therapy in Karachi, Pakistan. Only 9 children (37.5%) achieved adequate drug exposure. Target serum drug concentration was met in 4 (26.7%) of 15 children dosed consistently with World Health Organization recommendations and 4 (80.0%) of 5 who received higher-than-recommended doses. Levofloxacin dosing recommendations may require reevaluation.
Copyright © 2019 American Society for Microbiology.

Entities:  

Keywords:  Pakistan; children; fluoroquinolones; multidrug-resistant tuberculosis; pharmacokinetics

Year:  2019        PMID： 30803975      PMCID： PMC6496103          DOI： 10.1128/AAC.02569-18

Source DB:  PubMed          Journal:  Antimicrob Agents Chemother        ISSN： 0066-4804            Impact factor:   5.191


  9 in total

1.  Pharmacokinetics and Dosing of Levofloxacin in Children Treated for Active or Latent Multidrug-resistant Tuberculosis, Federated States of Micronesia and Republic of the Marshall Islands.

Authors:  Sundari R Mase; John A Jereb; Daniel Gonzalez; Fatma Martin; Charles L Daley; Dorina Fred; Ann M Loeffler; Lakshmy R Menon; Sapna Bamrah Morris; Richard Brostrom; Terence Chorba; Charles A Peloquin
Journal:  Pediatr Infect Dis J       Date:  2016-04       Impact factor: 2.129

Review 2.  Therapeutic drug monitoring in the treatment of tuberculosis: an update.

Authors:  Abdullah Alsultan; Charles A Peloquin
Journal:  Drugs       Date:  2014-06       Impact factor: 9.546

3.  Pharmacokinetics of ofloxacin and levofloxacin for prevention and treatment of multidrug-resistant tuberculosis in children.

Authors:  S Thee; A J Garcia-Prats; H M McIlleron; L Wiesner; S Castel; J Norman; H R Draper; P L van der Merwe; A C Hesseling; H S Schaaf
Journal:  Antimicrob Agents Chemother       Date:  2014-02-18       Impact factor: 5.191

4.  Evaluation of young children in contact with adult multidrug-resistant pulmonary tuberculosis: a 30-month follow-up.

Authors:  H Simon Schaaf; Robert P Gie; Magdalene Kennedy; Nulda Beyers; Peter B Hesseling; Peter R Donald
Journal:  Pediatrics       Date:  2002-05       Impact factor: 7.124

5.  Increased Doses Lead to Higher Drug Exposures of Levofloxacin for Treatment of Tuberculosis.

Authors:  Charles A Peloquin; Patrick P J Phillips; Carole D Mitnick; Kathleen Eisenach; Ramonde F Patientia; Leonid Lecca; Eduardo Gotuzzo; Neel R Gandhi; Donna Butler; Andreas H Diacon; Bruno Martel; Juan Santillan; Kathleen Robergeau Hunt; Dante Vargas; Florian von Groote-Bidlingmaier; Carlos Seas; Nancy Dianis; Antonio Moreno-Martinez; Pawandeep Kaur; C Robert Horsburgh
Journal:  Antimicrob Agents Chemother       Date:  2018-09-24       Impact factor: 5.191

6.  Treatment for LTBI in contacts of MDR-TB patients, Federated States of Micronesia, 2009-2012.

Authors:  S Bamrah; R Brostrom; F Dorina; L Setik; R Song; L M Kawamura; A Heetderks; S Mase
Journal:  Int J Tuberc Lung Dis       Date:  2014-08       Impact factor: 2.373

7.  Pharmacokinetics, Safety, and Dosing of Novel Pediatric Levofloxacin Dispersible Tablets in Children with Multidrug-Resistant Tuberculosis Exposure.

Authors:  Paolo Denti; Anneke C Hesseling; Anthony J Garcia-Prats; Susan E Purchase; Muhammad Osman; Heather R Draper; H Simon Schaaf; Lubbe Wiesner
Journal:  Antimicrob Agents Chemother       Date:  2019-03-27       Impact factor: 5.191

8.  Levofloxacin Population Pharmacokinetics in South African Children Treated for Multidrug-Resistant Tuberculosis.

Authors:  Paolo Denti; Anthony J Garcia-Prats; Heather R Draper; Lubbe Wiesner; Jana Winckler; Stephanie Thee; Kelly E Dooley; Rada M Savic; Helen M McIlleron; H Simon Schaaf; Anneke C Hesseling
Journal:  Antimicrob Agents Chemother       Date:  2018-01-25       Impact factor: 5.191

9.  Preventive therapy for child contacts of multidrug-resistant tuberculosis: a prospective cohort study.

Authors:  James A Seddon; Anneke C Hesseling; Heather Finlayson; Katherine Fielding; Helen Cox; Jennifer Hughes; Peter Godfrey-Faussett; H Simon Schaaf
Journal:  Clin Infect Dis       Date:  2013-09-24       Impact factor: 9.079
  9 in total
  1 in total

Review 1.  Treatment of Rifampicin-Resistant Tuberculosis Disease and Infection in Children: Key Updates, Challenges and Opportunities.

Authors:  Pauline Howell; Jay Achar; G Khai Lin Huang; Andrei Mariandyshev; H Simon Schaaf; Anthony J Garcia-Prats
Journal:  Pathogens       Date:  2022-03-23
  1 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.